{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:18:35Z","timestamp":1785525515364,"version":"3.56.0"},"reference-count":43,"publisher":"European Respiratory Society (ERS)","issue":"6","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Amsterdam Medical Center Foundation"},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["101005142"],"award-info":[{"award-number":["101005142"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10430 01 201 0007"],"award-info":[{"award-number":["10430 01 201 0007"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2022,6,23]]},"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Imatinib reduced 90-day mortality in hospitalised coronavirus disease 2019 (COVID-19) patients in a recent clinical trial, but the biological effects that cause improved clinical outcomes are unknown. We aimed to determine the biological changes elicited by imatinib in patients with COVID-19 and what baseline biological profile moderates the effect of imatinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We undertook a secondary analysis of a randomised, double-blind, placebo-controlled trial of oral imatinib in hospitalised, hypoxaemic COVID-19 patients. Mediating effects of changes in plasma concentration of 25 plasma host response biomarkers on the association between randomisation group and 90-day mortality were studied by combining linear mixed effect modelling and joint modelling. Moderation of baseline biomarker concentrations was evaluated by Cox regression modelling. We identified subphenotypes using Ward's method clustering and evaluated moderation of these subphenotypes using the aforementioned method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>332 out of 385 participants had plasma samples available. Imatinib increased the concentration of surfactant protein D (SP-D), and decreased the concentration of interleukin-6, procalcitonin, angiopoietin (Ang)-2\/Ang-1 ratio, E-selectin, tumour necrosis factor (TNF)-\u03b1, and TNF receptor I. The effect of imatinib on 90-day mortality was fully mediated by changes in these biomarkers. Cluster analysis revealed three host response subphenotypes. Mortality benefit of imatinib was only present in the subphenotype characterised by alveolar epithelial injury indicated by increased SP-D levels in the context of systemic inflammation and endothelial dysfunction (hazard ratio 0.30, 95% CI 0.10\u20130.92).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The effect of imatinib on mortality in hospitalised COVID-19 patients is mediated through modulation of innate immune responses and reversal of endothelial dysfunction, and possibly moderated by biological subphenotypes.<\/jats:p><\/jats:sec>","DOI":"10.1183\/13993003.00780-2022","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T05:44:58Z","timestamp":1658987098000},"page":"2200780","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients"],"prefix":"10.1183","volume":"60","author":[{"given":"Justin","family":"de Brabander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5547-5578","authenticated-orcid":false,"given":"Erik","family":"Duijvelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Job R.","family":"Schippers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Smeele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3145-864X","authenticated-orcid":false,"given":"Hessel","family":"Peters-Sengers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4254-3380","authenticated-orcid":false,"given":"Jan Willem","family":"Duitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurjan","family":"Aman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5371-0346","authenticated-orcid":false,"given":"Harm Jan","family":"Bogaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"van der Poll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2911-4549","authenticated-orcid":false,"given":"Lieuwe D.J.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"2024102103012067000_60.6.2200780.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12839.e4"},{"key":"2024102103012067000_60.6.2200780.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"},{"key":"2024102103012067000_60.6.2200780.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100433"},{"key":"2024102103012067000_60.6.2200780.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105911"},{"key":"2024102103012067000_60.6.2200780.5","doi-asserted-by":"crossref","first-page":"e210417","DOI":"10.1001\/jamanetworkopen.2021.0417","article-title":"Outcomes and mortality among adults hospitalized with COVID-19 at US medical centers","volume":"4","author":"Nguyen","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2024102103012067000_60.6.2200780.6","doi-asserted-by":"crossref","first-page":"103378","DOI":"10.1016\/j.ebiom.2021.103378","article-title":"Clinical features and prognostic factors in Covid-19: a prospective cohort study","volume":"67","author":"de Bruin","year":"2021","journal-title":"EBioMedicine"},{"key":"2024102103012067000_60.6.2200780.7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1164\/rccm.202106-1514OC","article-title":"Alveolar, endothelial, and organ injury marker dynamics in severe COVID-19","volume":"205","author":"Leisman","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102103012067000_60.6.2200780.8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.134304"},{"key":"2024102103012067000_60.6.2200780.9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085231"},{"key":"2024102103012067000_60.6.2200780.10","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00031.2015"},{"key":"2024102103012067000_60.6.2200780.11","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2213-2600(21)00237-X","article-title":"Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial","volume":"9","author":"Aman","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024102103012067000_60.6.2200780.12","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S2213-2600(22)00052-2","article-title":"Long-term clinical outcomes of COVID-19 patients treated with imatinib","volume":"10","author":"Duijvelaar","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2024102103012067000_60.6.2200780.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01643-9"},{"key":"2024102103012067000_60.6.2200780.14","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S2213-2600(20)30226-5","article-title":"Immunomodulation in COVID-19","volume":"8","author":"Ingraham","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024102103012067000_60.6.2200780.15","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S2665-9913(21)00353-2","article-title":"Who, what, and when-effective therapy for severe COVID-19","volume":"4","author":"Kelmenson","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2024102103012067000_60.6.2200780.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41385-021-00464-w"},{"key":"2024102103012067000_60.6.2200780.17","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v067.i0"},{"key":"2024102103012067000_60.6.2200780.18","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/biom.13475","article-title":"Quantifying direct and indirect effect for longitudinal mediator and survival outcome using joint modeling approach","volume":"78","author":"Zheng","year":"2022","journal-title":"Biometrics"},{"key":"2024102103012067000_60.6.2200780.19","unstructured":"Pinheiro J . nlme: linear and nonlinear mixed effects models. R package version 3.1\u2013157. 2022. https:\/\/cran.r-project.org\/web\/packages\/nlme Date last accessed: 4 April 2022 ."},{"key":"2024102103012067000_60.6.2200780.20","unstructured":"Therneau TM . A package for survival analysis in R. R package version 3.3\u20131. 2022. https:\/\/cran.r-project.org\/web\/packages\/survival Date last accessed: 4 April 2022 ."},{"key":"2024102103012067000_60.6.2200780.21","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v035.i03"},{"key":"2024102103012067000_60.6.2200780.22","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v076.i01"},{"key":"2024102103012067000_60.6.2200780.23","unstructured":"Kassambara A , Kosinski M , Biecek P , et al. survminer: drawing survival curves using \u2018ggplot2\u2019. 2022. https:\/\/cran.r-project.org\/web\/packages\/survminer\/index.html Date last accessed: 4 April 2022 ."},{"key":"2024102103012067000_60.6.2200780.24","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v061.i06"},{"key":"2024102103012067000_60.6.2200780.25","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-209719"},{"key":"2024102103012067000_60.6.2200780.26","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jaci.2018.09.030","article-title":"Imatinib stimulates prostaglandin E2 and attenuates cytokine release via EP4 receptor activation","volume":"143","author":"Barnthaler","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2024102103012067000_60.6.2200780.27","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00323.2014"},{"key":"2024102103012067000_60.6.2200780.28","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S2213-2600(20)30404-5","article-title":"Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes","volume":"8","author":"Leisman","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024102103012067000_60.6.2200780.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01499-z"},{"key":"2024102103012067000_60.6.2200780.30","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024102103012067000_60.6.2200780.31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S2213-2600(21)00494-X","article-title":"Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial","volume":"10","author":"Temesgen","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2024102103012067000_60.6.2200780.32","doi-asserted-by":"publisher","DOI":"10.1378\/chest.108.5.1303"},{"key":"2024102103012067000_60.6.2200780.33","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-216256"},{"key":"2024102103012067000_60.6.2200780.34","doi-asserted-by":"crossref","first-page":"664209","DOI":"10.3389\/fimmu.2021.664209","article-title":"Pulmonary procoagulant and innate immune responses in critically ill COVID-19 patients","volume":"12","author":"Nossent","year":"2021","journal-title":"Front Immunol"},{"key":"2024102103012067000_60.6.2200780.35","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-2600(14)70097-9","article-title":"Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials","volume":"2","author":"Calfee","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2024102103012067000_60.6.2200780.36","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202105-1302oc"},{"key":"2024102103012067000_60.6.2200780.37","doi-asserted-by":"crossref","first-page":"100829","DOI":"10.1016\/j.eclinm.2021.100829","article-title":"Identifying clinical and biochemical phenotypes in acute respiratory distress syndrome secondary to coronavirus disease-2019","volume":"34","author":"Ranjeva","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2024102103012067000_60.6.2200780.38","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S2213-2600(21)00365-9","article-title":"Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts","volume":"9","author":"Bos","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024102103012067000_60.6.2200780.39","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-10-6"},{"key":"2024102103012067000_60.6.2200780.40","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.11.983"},{"key":"2024102103012067000_60.6.2200780.41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4245"},{"key":"2024102103012067000_60.6.2200780.42","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201603-0645OC"},{"key":"2024102103012067000_60.6.2200780.43","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-2600(18)30177-2","article-title":"Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial","volume":"6","author":"Calfee","year":"2018","journal-title":"Lancet Respir Med"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00780-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:08:21Z","timestamp":1740380901000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00780-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,12,15]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1183\/13993003.00780-2022"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00780-2022","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]}}}